Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Opioid Treatment topic
No spam. Unsubscribe anytime.
House committee advances methadone-access bill after hours of debate over clinics and local control
Summary
The House Health Committee voted 13–6 to advance HB 2100, which would remove a certificate-of-need requirement for certain methadone prescribing while preserving physician oversight. Members debated clinic siting, zoning, patient safety and international examples during an extended exchange.
The Tennessee House Health Committee advanced House Bill 2100 to the Finance, Ways and Means Committee by a 13–6 vote after more than an hour of discussion on methadone access and local control.
The sponsor (Sponsor, House Bill 2100) told the committee methadone is legal in Tennessee and “is a safe gateway out of illegal substances,” arguing the bill would remove a separate certificate-of-need requirement while retaining physician oversight at facilities. He said facilities would still need a doctor on site and all other current requirements would remain in place.
Several members raised concerns about community impacts and zoning. Chairman Williams said a clinic seeking to locate in Cookeville had difficulty finding a site under city zoning and ultimately located outside city limits; he asked what remedies residents would have if COs were removed and zoning did not prevent a clinic near sensitive sites such as schools. The sponsor replied that local ordinances and zoning would continue to apply and that the bill simply removes the CO process that many communities currently use.
Chairman Kumar questioned whether the proposal resembled models used elsewhere, noting Oregon’s experience had led to policy reversals. The sponsor distinguished the proposal from Oregon’s approach, saying it was not intended to legalize illicit drug use but to expand access to medically supervised treatment at counseling and rehabilitation facilities that employ a physician.
Other members praised methadone and buprenorphine as established treatments for opioid use disorder, with supporters noting clinical uses in hospitals can reduce post‑operative opioid needs. Opponents warned about diversion risk and emphasized clinic location and oversight as determinants of success.
The committee’s vote advances HB 2100 to Finance, Ways and Means. The bill’s next procedural step is committee consideration in that chamber.
